parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.07 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in epididymal principal cells	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 3870

receipt 3878: ARVCF in dopamine neurons, braak

power: full sample -0.37 (p 0.132, n 18), 95% CI -0.71 to +0.12. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.35 (p 0.156, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.049, n 18). not the mix.
skeptic: leave-one-out range -0.49 to -0.29, sign flips 0; without severely affected donors -0.37 (p 0.132, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ARVCF in dopamine neurons.

case closed: nothing better to follow up.

receipt 3877: ARVCF in astrocytes, braak

power: full sample -0.12 (p 0.646, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.18 (p 0.476, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.14 (p 0.573, n 18). could be the mix.
skeptic: leave-one-out range -0.24 to -0.02, sign flips 0; without severely affected donors -0.12 (p 0.646, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ARVCF in astrocytes.

case closed: nothing better to follow up.

loading the receipts